Business Wire

NATURA-BISSÉ

Share
NATURA BISSÉ and ARCH AMENITIES GROUP EUROPE Announce a Strategic Collaboration in the EU Market and the UK

Natura Bissé & Arch Amenities Group Europe have announced a formal collaboration to increase their collective presence in the luxury spa sector across the EU and the United Kingdom. The agreement fosters strategic and complementary growth opportunities for both brands, which will reference each other, capitalizing on the well-established reputation of the Natura Bissé brand, its professional and retail skincare products and services and Arch Amenities Group’s experience in managing and operating pre-eminent luxury wellness centers and spas.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231122952800/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Barry Goldstein, CEO Arch Amenities Group (Photo: Natura Bissé)

The Spanish skincare firm, Natura Bissé, currently has a presence in more than 450 spa hotels around the world—35% of which are located in Europe—and is set to close the year with a total revenue of 100 million euros. With its headquarters in Barcelona, 82% of the company’s sales are recorded abroad, with the Unites States and China being its primary markets, followed by Spain. Over the next 3 years, Europe will become the company’s strategic focus with the aim of doubling its multi-channel presence in this region.

For its part, Arch Amenities Group and its 3800 employees currently manage over 430 properties around the world. Private clubs, fitness centers, commercial and residential spaces and, of course, hotels place their trust in the Group’s extensive experience. Among the hotel groups in their portfolio of clients are big names like Waldorf Astoria, Four Seasons and The Ritz-Carlton, who are also partners of Natura Bissé across the world.

Natura Bissé has been part of Arch Amenities Group’s Preferred Vendor Program since early 2023, connecting the Natura Bissé product suite to a host of renowned U.S.-based spas and wellness spaces such as the Eden Roc Miami Beach Resort or the Waldorf Astoria Washington DC.

Today this partnership adopts a new character as a “non-exclusive strategic agreement” in Europe, at a time when the hospitality sector is seeing increased demand for elevated wellness experiences. Proof of this comes from data in a recent report from the Global Wellness Institute, which highlights consistent 12% annual growth in the wellbeing market since 2020 and forecasts a further 52% growth by 2027.

“This strategic agreement represents a step-change in the way both leading brands address the changing needs of the European market and reinforces our collective commitment to offer unlimited innovation, inspiration as a pillar of growth and bespoke agile solutions. That is why I’m convinced that our collaboration with Arch Amenities Group Europe will allow us to expand our presence in first-class spas and wellbeing centers,” says Verónica Fisas, CEO at Natura Bissé Group.

“Partnering with Natura Bissé in Europe to develop spas is an ideal fit for Arch as we grow our presence in Europe. As one of the most celebrated luxury skincare brands in the world, our strategic collaboration with Natura Bissé allows us to extend our proven expertise in developing and managing luxury wellness spaces to bring guests an unparalleled experience powered by great products, outstanding hospitality and elevated service,” says Barry Goldstein, CEO at Arch Amenities Group.

ABOUT ARCH AMENITIES GROUP

Arch Amenities Group, based in Rockville, Maryland, is a leading provider of hospitality management and consulting services for commercial and residential properties, hotels, spas and private clubs and recreation spaces worldwide. Arch provides daily management services as well as feasibility studies, planning and design consultancy as well as recruiting, pre-opening and sustaining strategy and support. Arch is a portfolio company of private equity firm CI Capital Partners.

ABOUT NATURA BISSÉ

Natura Bissé is a globally renowned luxury skincare company. Founded in Barcelona in 1979, Natura Bissé fuses pioneering technology with the most delicate human touch in order to listen and adapt to the differing needs of each and every client.

The constant pursuit of excellence has earned Natura Bissé numerous awards, notably recognition for being the “World’s Best Spa Brand” for four consecutive years (2018-2021).

With presence in 40 countries, Natura Bissé continues to expand around the world throughout the most distinguished luxury retailers and best-in-class spas.

In 2008 the brand helped establish the Ricardo Fisas Natura Bissé Foundation to contribute to the well-being of people in vulnerable situations. To support the Foundation’s initiatives, Natura Bissé has three fundraising lines of hotel toiletries.

Images available here.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231122952800/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Seoul Semiconductor: Philips Lighting Products Ordered to Recall 7-Year-Old Items26.12.2024 08:00:00 CET | Press release

The German District Court of Düsseldorf, on November 19 ruled in favor of Seoul Semiconductor (KOSDAQ:046890) in the patent infringement lawsuits, and also ordered that products manufactured by Philips Lighting and sold since March 2017 be recalled and destroyed. The Court also ruled that a fine of up to €250,000 would be imposed for each violation of this order. On December 17, the German Federal Patent Court also affirmed the validity of these patents, which solidifies the strength of many related patents. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241225151382/en/ Application Examples with CRI 70 or Higher (Photo: Seoul Semiconductor) These court orders relate to the core technology used to achieve CRI 70 (Color Rendering Index 70%) or higher, applicable to all home lighting, automotive lighting products, IT flash, and backlights. Since the effects of these judgments are applicable to all products infringing on the pa

ispace-EUROPE and the Italian Space Agency (ASI) Sign Payload Services Agreement to Transport a Laser Retroreflector Array (LaRA2) on the Moon Surface26.12.2024 08:00:00 CET | Press release

Agreement Marks Significant Step Towards Increasing Italy’s Contribution to advancing Lunar Exploration ispace EUROPE S.A. (ispace-EUROPE), the Luxembourg-based subsidiary of ispace, inc., and the Italian Space Agency (ASI) have signed a payload services agreement to transport a Laser Retroreflector Array (LaRA2) to enable accurate position measurements on the Moon via laser ranging experiments, the two organizations announced today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241225137548/en/ The shape of LaRA2, a palm-sized dome (Photo: Business Wire) The agreement marks the first full-scale contract between ispace-EUROPE and ASI, with both organizations looking to joint future lunar development. LaRA2 is a small, robust, and lightweight instrument built to work without any power source and to survive the harsh surface conditions on the Moon for an extended period of time. It features a precise array of retroreflectors

Datopotamab Deruxtecan Application in the EU for Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer Voluntarily Withdrawn24.12.2024 08:00:00 CET | Press release

Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/Nasdaq: AZN) have voluntarily withdrawn the marketing authorization application (MAA) in the EU for datopotamab deruxtecan (Dato-DXd) for the treatment of adult patients with locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) based on the TROPION-Lung01 phase 3 trial. The decision to withdraw the MAA was informed by feedback from the Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA). Daiichi Sankyo and AstraZeneca will continue to work to bring datopotamab deruxtecan to patients with lung cancer in the EU who can benefit and are committed to unlocking the potential of this medicine in lung cancer through our robust clinical development program which includes seven pivotal trials in various lung cancer settings. Datopotamab deruxtecan is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed by Dai

Vertex to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 1323.12.2024 22:05:00 CET | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Dr. Reshma Kewalramani, Chief Executive Officer and President, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 10:30 a.m. ET/7:30 a.m. PT. A live webcast of management's remarks will be available through the Vertex website, www.vrtx.com in the "Investors" section under the "News and Events" page. A replay of the conference webcast will be archived on the company's website. About Vertex Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has approved medicines that treat the underlying causes of multiple chronic, life-shortening genetic diseases — cystic fibrosis, sickle cell disease and transfusion-dependent beta thalassemia — and continues to advance clinical and research programs in these diseases. Vertex also has a robust clinical pipeline of investigational

Perma-Pipe International Holdings, Inc. Announces Third Quarter Financial Results23.12.2024 18:43:00 CET | Press release

The Company generated net sales of $41.6 million for the quarter and $113.4 million year-to-dateIncome before income taxes of $5.1 million for the quarter and $13.2 million year-to-dateBacklog of $114.2 million at October 31, 2024, compared to $68.5 million at January 31, 2024 Perma-Pipe International Holdings, Inc. (NASDAQ: PPIH) announced today financial results for the second quarter and fiscal year-to-date period ended October 31, 2024. "Net sales for the third quarter were $41.6 million, a decrease of $4.1 million, as compared to the same quarter last year. Net income attributable to common stock of $2.5 million was an increase of $0.5 million, or 29%, compared to $1.9 million in the third quarter of 2023. For the nine months ended October 31, 2024, net sales of $113.4 million represent an increase of 3% compared to the nine months ended October 31, 2023. The net income attributable to common stock of $7.2 million was an increase of $5.4 million, or 294%, compared to net income at

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye